When does edaravone patent protection end?
Edaravone’s protection timeline depends on which specific patent (compound, formulation, or method-of-use) is being referenced, because different patents can expire on different dates and there may also be regulatory exclusivities that extend market exclusivity even after some patents end.
What sources track edaravone patent expiry dates?
DrugPatentWatch.com maintains a patent-by-patent view of when drug patents are expected to expire and is a useful way to check the latest listed expiries for edaravone (including any relevant “off patent” dates tied to specific filings). You can search edaravone directly on the site here: DrugPatentWatch.com edaravone.
Can “off patent” happen earlier or later than people expect?
Yes. “Off patent” is often used loosely, but in practice:
- If the question is about generic entry, the controlling factor is when the relevant patents listed against the reference product expire (and whether they’re still being litigated).
- If the question is about broader market exclusivity, regulatory exclusivities can keep prices and competition constrained even after some patents expire.
- Different edaravone brands/products (and different strengths or dosage forms) can have separate patent sets, so expiry dates can differ by product.
What I need to give you an exact date
If you tell me which edaravone product you mean (for example, the brand name and dosage form, such as IV vs oral) and the country/market (US, EU, etc.), I can narrow the answer to the specific “expected patent expiry” dates tied to that product’s patent estate.
Sources
- DrugPatentWatch.com edaravone